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Retinoid X receptor (RXR) regulates several key functions in myeloid
cells, including inflammatory responses, phagocytosis, chemokine
secretion, and proangiogenic activity. Its importance, however, in
tumor-associated myeloid cells is unknown. In this study, we
demonstrate that deletion of RXR in myeloid cells enhances lung
metastasis formation while not affecting primary tumor growth.
We show that RXR deficiency leads to transcriptomic changes in the
lung myeloid compartment characterized by increased expression
of prometastatic genes, including important determinants of pre-
metastatic niche formation. Accordingly, RXR-deficient myeloid cells
are more efficient in promoting cancer cell migration and invasion.
Our results suggest that the repressive activity of RXR on prometa-
static genes is mediated primarily through direct DNA binding of
the receptor along with nuclear receptor corepressor (NCoR) and
silencing mediator of retinoic acid and thyroid hormone receptor
(SMRT) corepressors and is largely unresponsive to ligand activa-
tion. In addition, we found that expression and transcriptional ac-
tivity of RXRα is down-modulated in peripheral blood mononuclear
cells of patients with lung cancer, particularly in advanced and
metastatic disease. Overall, our results identify RXR as a regula-
tor in the myeloid cell-assisted metastatic process and establish
lipid-sensing nuclear receptors in the microenvironmental regu-
lation of tumor progression.
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Retinoid X receptor (RXR) is a member of the nuclear re-ceptor superfamily of ligand-dependent transcription factors
that bind various lipophilic hormones and lipid metabolites.
Sensing the lipid milieu by RXR, in concert with other nuclear
receptors, plays critical roles in physiology, including the regu-
lation of organogenesis, lipid metabolism, and skin homeostasis
(1). RXR is able to bind vitamin A derivatives 9-cis-retinoic acid
and 9-cis-13,14-dihydroretinoic acid as well as fatty acids such as
docosahexanoic acid and phytanic acid (1, 2). The receptor has
three isotypes, RXRα, RXRβ, and RXRγ, which appear to be
functionally interchangeable in tissues in which more than one
isotype is expressed (3). RXR has a unique integrative function
in nuclear receptor signaling because of its ability to form
homodimers as well as heterodimers with several other members
of the superfamily, such as PPAR, LXR, RAR, and VDR. RXR
and its heterodimers have a profound effect on the function of
myeloid cells by linking cellular metabolism and immune func-
tion (4, 5). Specific activation of RXR has been shown to
up-regulate chemokine expression, promote phagocytosis of
apoptotic cells, and attenuate antiviral responses in myeloid cells
(6–8). To further delineate the function of the receptor, we re-
cently mapped the genomic binding sites of RXR in macrophages
and identified a network of RXR-bound enhancers that control
angiogenic genes including Vegfa, Hbegf, Litaf, and Hipk2 (9).
Activation of these enhancers by RXR induced a proangiogenic
transcriptional program and phenotype (9). Interestingly, we
found that half of the 5,200 RXR-occupied genomic sites were
transcriptionally inactive in macrophages (9). This suggested that
the receptor may also possess extensive regulatory functions in
myeloid cells that are distinct from ligand recognition and acti-
vation. These observations provided a rationale to investigate
whether RXR influences tumor progression through regulating
the phenotype of recruited or tissue-resident myeloid cells.
Results
RXR Deletion in Myeloid Cells Promotes Metastasis to the Lung. In
myeloid cells, RXRα shows the highest expression and RXRβ is
expressed at a lower level, while RXRγ is not expressed (5).
Specific deletion of RXRα in myeloid cells was achieved by
crossing mice bearing lox-P-targeted RXRα (RXRαfl/fl) with
mice carrying the lysozyme-M Cre (LysM-Cre) recombinase
transgene. To exclude the potential compensatory effects of
RXRβ in the absence of RXRα resulting from the functional
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redundancy of RXR isotypes (3, 10), we crossed LysM-Cre
RXRαfl/fl with RXRβ−/− mice. Given the low fertility and via-
bility of the resulting LysM-Cre RXRαfl/fl RXRβ−/− mice (11),
we transplanted their bone marrow to syngeneic C57BL/6J mice.
This way, we were able to generate age-matched groups of mice
bearing LysM-Cre RXRαfl/fl RXRβ−/− and LysM-Cre RXRα+/+
RXRβ−/− bone marrow (hereafter referred to as RXRαfl/fl and
RXRα+/+, respectively).
To investigate the effect of RXRα deletion in the myeloid in-
filtrate on tumor progression, we s.c. implanted RXRαfl/fl and
RXRα+/+mice with Lewis lung carcinoma (LLC), a murine model
of non-small cell lung carcinoma showing abundant infiltration of
myeloid cells from early stages. Primary tumor growth remained
unaltered (Fig. 1A), and the immune cell infiltration in RXRαfl/fl
mice was largely unaltered with a significantly lower abundance of
M1-like CD11b+Ly6G−Ly6C−MHC-IIhigh macrophages (SI Ap-
pendix, Fig. S1). However, the frequency of M2-like MHC-IIlow
macrophages and other immune cell populations was not affected
by RXRα deficiency (SI Appendix, Fig. S1). Although primary
tumor growth was not affected, we observed a higher frequency of
animals with spontaneous lung metastases, as well as a higher
number of metastatic nodules in the RXRα knock-outs compared
with controls (Fig. 1 B and C). Thus, we further investigated the
role of myeloid cell-expressed RXRα in lung colonization by using
an experimental metastasis model. Consistent with the results
obtained in the LLC model, we found that B16-F10 melanoma
cells formed a higher number of macroscopic and microscopic
metastases in the lungs of RXRαfl/fl mice after i.v. injection (Fig. 2
A–C). RXRαfl/fl lungs contained a considerably higher frequency
of micrometastases with diameters less than 100 μm, demon-
strating that extravasation followed by micrometastasis formation
in the lung is more efficient in the presence of RXRα-deficient
myeloid cells (Fig. 2D). Since survival and proliferation of
extravasated cancer cells at the distant organ is a critical early
step of metastasis, we also examined the effect of myeloid cell
RXRα on the apoptotic and mitotic rate of metastatic cancer
cells. Staining of B16-F10 lung metastases with Ki67, a marker of
cell proliferation, did not show major differences between
RXRαfl/fl and RXRα+/+ lungs (Fig. 2E). The apoptosis rate, as
assessed by staining of cleaved caspase-3, was not significantly
different in metastases of RXRαfl/fl lungs either (Fig. 2E). This
suggested that myeloid-specific RXRα deficiency does not af-
fect the proliferation or survival of metastatic cancer cells in
the lung, and the enhanced metastasis rate in RXRαfl/fl mice
originates principally from enhanced lung colonization. Alto-
gether, these results indicate that deletion of RXRα in the
myeloid compartment generates a lung microenvironment that is
more permissive toward metastasis formation.
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Fig. 1. RXRα deletion in myeloid cells enhances Lewis lung carcinoma me-
tastasis. (A) Subcutaneous LLC tumor growth in mice with myeloid cell-specific
deletion of RXRα (RXRαfl/fl) and control (RXRα+/+) mice (n = 5–7/group).
(B) Number of macroscopic lung metastases in RXRαfl/fl and RXRα+/+ mice (*P <
0.05, Mann-Whitney test, n = 15/group, data combine two independent ex-
periments). (C) Representative images of hematoxylin and eosin-stained mid-
coronal lung sections from RXRαfl/fl and RXRα+/+ mice. Arrowheads indicate
metastatic nodules. (Scale bar, 1 mm.) Graphs on A and B show mean ± SEM.
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Fig. 2. RXRα deletion in myeloid cells results in enhanced lung colonization
by B16-F10 melanoma cells. (A) Number of macroscopic lung metastases in
RXRαfl/fl and RXRα+/+ mice (*P < 0.05, unpaired Student’s t test, n = 10–13/
group, data combine two independent experiments). (B) Number of micro-
scopic lung metastases on midcoronal lung sections in RXRαfl/fl and RXRα+/+
mice (*P < 0.05, unpaired Student’s t test, n = 8/group). (C) Representative
images of hematoxylin and eosin-stained midcoronal lung sections from
RXRαfl/fl and RXRα+/+ mice. (Scale bar, 6 mm.) (D) Size distribution of B16-
F10 melanoma lung metastases with a diameter ≤1,000 μm in RXRαfl/fl and
RXRα+/+ mice. Metastasis diameter data are pooled from eight lungs/group.
(E) Representative images and quantification of Ki67 and cleaved caspase-
3 stainings on midcoronal lung sections with B16-F10 melanoma metastases
from RXRαfl/fl and RXRα+/+ mice (Scale bar, 100 μm.) (P > 0.05, unpaired
Student’s t test, n = 5/group). Bar graphs on A, B, and E show mean ± SEM.
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RXR Represses a Prometastatic Gene Set in Pulmonary Myeloid Cells.
Our results showing enhanced lung colonization of cancer cells
in mice with myeloid-specific RXRα deficiency prompted us to
investigate whether the absence of RXRα has any effect on the
abundance or phenotype of pulmonary myeloid cells. Flow
cytometry analysis of the pulmonary myeloid compartment
revealed that the lack of RXRα was associated with slightly
decreased numbers of CD45+CD11b+F4/80+Ly6G− lung mac-
rophages in naive mice (Fig. 3A). In contrast, neither the resi-
dent population nor the metastasis-induced recruitment of
CD45+CD11b+F4/80−Ly6G+ neutrophils was affected by the
absence of myeloid RXRα (Fig. 3A). Along with metastasis-
associated macrophages differentiated from inflammatory mono-
cytes, lung-resident macrophages have recently been reported to
promote the formation of lung metastases (12). Accordingly,
LysM-Cre-mediated deletion of an RXR heterodimeric partner
PPARγ in myeloid cells results in a moderate decrease of alveolar
macrophages (13), and these mice develop fewer pulmonary
metastases (14). For these reasons, we assumed that the increase
in metastasis formation cannot be explained by the decreased
number of lung-resident macrophages in RXRαfl/fl mice. Thus, we
decided to investigate whether the lack of RXRα can alter the
phenotype of pulmonary myeloid cells, resulting in a more per-
missive tissue environment for metastatic cancer cells. To char-
acterize the cellular consequences of RXRα deletion in myeloid
cells, we performed transcriptomic analysis via RNA sequencing
on the CD45.2+CD11b+ myeloid compartment isolated from naive
lungs of RXRα+/+ and RXRαfl/fl mice. Expression of the CD45.2
pan-leukocyte antigen by CD11b+ myeloid cells confirmed their
transplanted bone marrow origin. We found 1,284 differentially
expressed genes (adjusted P value < 0.01) comparing RXRα+/+ and
RXRαfl/fl cells (Fig. 3B and Dataset S1). Interestingly, gene ontol-
ogy analysis identified “regulation of cell migration” and “positive
regulation of cell migration” along with “cytokine-mediated sig-
naling pathway” as the most significantly enriched biological pro-
cesses among the genes up-regulated in RXRα-deficient pulmonary
myeloid cells (Fig. 3C). Using Ingenuity Pathway Analysis as an
alternative approach yielded similar results (SI Appendix, Table S1).
Accordingly, within the RXRα-repressed gene set, we could iden-
tify a number of genes encoding secreted factors that have been
previously described to promote metastasis, including inflammatory
mediators (C1qa, Il1a, Il1b, Tnf, Lcn2), growth factors (Gas6,
Hbegf, Igf1, Pdgfa, Pdgfb), extracellular matrix proteins (Ecm1,
Vcan), matrix-degrading proteases (Mmp2, Ctsb, Ctss), proin-
flammatory S100 calcium-binding proteins (S100a4, S100a8),
and the proinvasive secreted semaphorin, Sema4d (Fig. 3D and
SI Appendix, Table S2). In addition, upstream regulator analysis
of differentially expressed genes in RXRα-deficient myeloid cells
predicted the activation of several inflammatory pathways in-
cluding TNF, TLR2, and TLR4, which have a crucial role in ini-
tiating an inflammatory microenvironment in the lung, thereby
promoting metastatic colonization (15, 16) (SI Appendix, Table S3).
These results strongly suggested that RXRα constitutively re-
presses a large set of genes involved in the positive regulation of cell
migration and metastasis formation. This led us to hypothesize that
the relief of repression (de-repression) of these genes in the absence
of RXRα results in a migration-promoting phenotype in myeloid
cells. To test this hypothesis, we used RXRαfl/fl and RXRα+/+ im-
mortalized bone marrow-derived macrophages (iBMDM). As
expected, based on the migration-promoting transcriptomic signa-
ture induced in the absence of RXRα, RXRαfl/fl iBMDMs were
significantly more efficient in promoting the migration of LLC cells
compared with RXRα+/+ cells (Fig. 3E and SI Appendix, Fig. S2A).
Interestingly, RXRα deficiency increased not only the migration-
promoting activity of iBMDMs but also their proinvasive effect.
LLC cells were more efficient in invading through a Matrigel
extracellular matrix layer in the presence of RXRα-deficient
iBMDMs (Fig. 3F and SI Appendix, Fig. S2B). While enhancing
cancer cell migration and invasion, RXRα-deficient iBMDMs did
not promote cancer cell proliferation (SI Appendix, Fig. S2C).
Overall, these results indicate that the transcriptomic signature
generated by RXRα-deficiency in myeloid cells translates to a
metastasis-promoting cellular phenotype.
RXR-Mediated Repression of Prometastatic Genes Is Predominantly
Ligand-Insensitive. Next, we sought to determine whether the
RXR-mediated repression in myeloid cells can be enhanced or
suspended by the presence of an RXR-activating ligand. To
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Fig. 3. RXRα represses a prometastatic gene set in pulmonary myeloid cells.
(A) Relative numbers of myeloid cells in the lungs of RXRα+/+ and RXRαfl/fl mice
in the presence or absence of B16-F10 melanoma metastases (*P < 0.05, un-
paired Student’s t test, n = 3/group). (B) Volcano plot showing transcriptomic
differences in CD45+CD11b+ pulmonary myeloid cells from RXRαfl/fl mice
compared with RXRα+/+. Red dots represent differentially expressed genes
(adjusted P < 0.01, Wald test, n = 3/group). (C) Dot plot showing significantly
enriched gene ontology biological processes within the up-regulated genes in
RXRαfl/fl pulmonary myeloid cells. The top five enriched GO terms by P value
are highlighted. (D) Heat map showing expression changes of selected
prometastatic genes in RXRα+/+ and RXRαfl/fl pulmonary myeloid cells.
(E) Number of migrated LLC cells in the presence of RXRα+/+ or RXRαfl/fl
iBMDMs in Transwell migration assay. The experimental setup is shown in SI
Appendix, Fig. S2A (***P < 0.001, unpaired Student’s t test, n = 3/group).
(F) Number of migrated LLC cells through Matrigel layer in the presence of
RXRα+/+ or RXRαfl/fl iBMDMs in Transwell invasion assay. The experimental
setup is shown in SI Appendix, Fig. S2B (*P < 0.05, unpaired Student’s t test,
n = 3/group). Bar graphs on A, E, and F show mean ± SEM.
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answer this, we used our previously published RNA-seq data from
BMDMs treated with a highly selective, synthetic RXR agonist
LG268 (9). The short-term ligand activation (30/60/120 min)
enabled us to exclude secondary transcriptional changes after
activation of the receptor. By examining the ligand response of
RXR-repressed genes identified in pulmonary myeloid cells, we
found that only a small fraction of them (14.1%) showed gene
expression change in response to RXR activation (8/2, 29/3, 58/
25 up-/down-regulated from 695 after 30, 60, 120 min of LG268
stimulation, respectively) (Fig. 4A). In the previously described
prometastatic gene set, only Hbegf, Pdgfa, and Pdgfb showed sig-
nificant up-regulation on ligand stimulus (Fig. 4B). This suggested
that the majority of RXR-repressed genes in myeloid cells (in-
cluding genes with prometastatic effect) cannot be modulated
by RXR agonists. This was further supported by the observation
that the cancer cell migration-promoting activity of iBMDMs
was not altered after pretreatment with selective RXR agonist
LG268 (Fig. 4C).
RXR Colocalizes with NCoR/SMRT Corepressors to Mediate Repression
of Prometastatic Genes. Unliganded RXR homodimers and het-
erodimers bind the promoters and/or enhancers of their target
genes in association with corepressors nuclear receptor co-
repressor (NCoR) or silencing mediator of retinoic acid and
thyroid hormone receptor (SMRT). Using our previously pub-
lished RXR ChIP-seq dataset from BMDMs (9), we determined
which genes show RXR binding in the proximity of their tran-
scription start site (±100 kb) at the genome-wide level. In-
triguingly, gene ontology analysis of these RXR-bound genes
revealed a significant overrepresentation of genes involved in the
regulation of cell migration and activation of the immune re-
sponse (SI Appendix, Fig. S3). This suggested that the major
genomic targets of RXR binding (and possibly repression) in the
steady state are genes that can be functionally linked to cell
migration and inflammation. Next, we focused on genes that are
repressed by RXR in pulmonary myeloid cells and examined
whether RXR binding sites can be found in the vicinity of them.
We could detect RXR binding sites within 100 kb of the tran-
scription start sites in 66% of RXR-repressed genes. This sug-
gested that direct DNA binding by the receptor accounts for
its repressive effect by the majority of repressed genes. As
mentioned earlier, NCoR and SMRT corepressors are the most
common interacting partners of RXR in mediating transcrip-
tional repression. To determine whether RXR binding is asso-
ciated with NCoR or SMRT binding at RXR-repressed genes,
we combined our RXR ChIP-seq data with public NCoR and
SMRT ChIP-seq datasets from BMDMs (17). Interestingly, 59%
of RXR binding sites detected in the vicinity of RXR-repressed
genes showed overlap with both NCoR and SMRT, while 12%
and 7% showed overlap with only NCoR or only SMRT, re-
spectively. In addition, NCoR and SMRT occupancy in the
proximity of RXR-repressed genes was higher at genomic sites
where RXR was also present, suggesting that the presence of
RXR facilitates the binding of these corepressors (Fig. 5A).
When we examined the genomic loci of the members of RXR-
repressed prometastatic gene set identified in pulmonary mye-
loid cells, we detected overlapping RXR/NCoR/SMRT binding
in the close proximity of 11 of the 18 genes (Fig. 5B). It has been
shown previously that nuclear receptor-mediated transcriptional
repression largely required either NCoR alone or both NCoR
and SMRT, only a small fraction of genes showing repression
specifically by SMRT (18). Accordingly, deletion of the domi-
nant corepressor NCoR in iBMDMs resulted in the up-regula-
tion of Il1a, Il1b, Pdgfb, Sema4d, Igf1, and Ctss, confirming the
requirement of NCoR for the repression of these genes (Fig.
5C). Lack of de-repression by several RXR/NCoR/SMRT-bound
genes in NCoR-deficient iBMDMs suggested the existence of
compensatory mechanisms emerging in the absence of NCoR, as
reported previously (19).
RXR Signaling Is Down-Modulated in Peripheral Blood Mononuclear
Cells of Patients with Non-Small Cell Lung Cancer. Finally, we set out
to determine whether any alterations in RXR signaling can be
observed in patients with cancer. Deletion of RXRα in mice
results in embryonic lethality caused by abnormal development
of the heart (1). Similarly, DNA sequence data from the Exome
Aggregation Consortium showed that loss-of-function mutations
in genes coding any of the RXR isotypes are highly improbable,
with a probability of loss-of-function intolerance of 94%, 100%,
and 94% for RXRα, RXRβ, and RXRγ, respectively (20). Thus,
since loss-of-function mutations of RXR are predicted to be very
rare, we aimed to investigate whether any changes in RXR ex-
pression can be observed in myeloid cells of patients with cancer
that could potentially influence its repressive activity. As ex-
pression data from tissue-resident or metastasis-associated my-
eloid cells is difficult to obtain in the case of patients with cancer,
we decided to analyze gene expression changes in peripheral
blood mononuclear cells (PBMCs). PBMCs have been described
to exhibit distinct gene expression changes in a number of ma-
lignancies (21–23). We chose to analyze the gene expression of
PBMCs from patients with non-small cell lung cancer (NSCLC)
and cancer-free control patients, using the largest publicly
available dataset including samples from 137 patients with
NSCLC and 91 cancer-free control patients (22). Intriguingly, we
found that PBMCs from patients with NSCLC showed a signif-
icantly lower expression of RXRα (Fig. 6A). In addition, the
mean expression level of RXRα exhibited decreasing kinetics
during disease progression, showing the lowest expression in
patients with advanced and metastatic disease (stage III-IV)
(Fig. 6A). RXRβ and RXRγ isotypes displayed lower average
expression than RXRα in PBMCs and did not show any changes
in patients with NSCLC (Fig. 6A). These data showed that
RXRα, the dominant RXR isotype expressed in myeloid cells,
was down-regulated in individuals with NSCLC, and its de-
creased expression was not compensated for by the up-regulation
of other RXR isotypes. Next, we wanted to determine whether
down-regulation of RXRα in patients with lung cancer is asso-
ciated with its altered transcriptional activity. RXR’s activity can
be assessed by examining the regulation of the target genes of its
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Fig. 4. RXR-mediated repression of prometastatic genes is predominantly
ligand-insensitive. (A) Heat map showing expression changes in response to
synthetic RXR agonist LG268 in BMDMs among RXR-repressed genes iden-
tified in pulmonary myeloid cells (adjusted P < 0.01, Wald test, n = 2/time
point). (B) Heat map showing expression changes in response to synthetic
RXR agonist LG268 in BMDMs among selected RXR-repressed prometastatic
genes identified in pulmonary myeloid cells. Genes with significant expres-
sion changes are shown in bold italics (adjusted P < 0.01, Wald test, n = 2/
group). (C) Number of migrated LLC cells in the presence of control or
LG268-pretreated iBMDMs in Transwell migration assay (P > 0.05, unpaired
Student’s t test, n = 3/group).
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heterodimeric partners, since specific target genes for homodi-
meric RXR signaling have not been unequivocally established. To
identify transcriptional regulators that show altered activity in
NSCLC, we determined the differentially expressed genes be-
tween PBMCs of patients with NSCLC and cancer-free control
patients and performed an upstream regulator prediction on these
genes using Ingenuity Pathway Analysis. Interestingly, among the
top 10 upstream regulators whose activity was predicted to be
strongly inhibited in patients with NSCLC, we found two nuclear
receptors, PPARγ and LXRα, that require RXR as a hetero-
dimeric partner for their transcriptional activity (Fig. 6B). The
inhibited transcriptional activity of PPARγ/RXR and LXRα/RXR
heterodimers in patients with NSCLC could not be explained by
the down-regulated expression of PPARγ and LXRα, as their ex-
pression remained unaltered (SI Appendix, Fig. S4). Overall, these
data suggest that the expression and transcriptional activity of
RXRα is down-modulated in the immune system of patients with
NSCLC, particularly in advanced and metastatic disease.
Discussion
Our study demonstrates that RXRα expressed by myeloid cells
in the lung is essential to maintain a metastasis-resistant tissue
microenvironment. Our data suggest that steady-state transcrip-
tional repression by RXR, partly in concert with NCoR and
SMRT corepressors in myeloid cells, controls the expression of
several genes whose protein products facilitate the metastatic
spread of cancer cells in distant organs. RXR appears to be
unique in its ability to form homodimers, as well as heterodimers,
with a diverse range of nuclear receptors. Therefore, it is possible
that prometastatic genes in pulmonary myeloid cells are repressed
both by RXR homodimers and heterodimers. However, the rel-
ative contribution of homo- and heterodimers is difficult to de-
termine, since they show redundancy in their binding site
preferences, and target genes regulated exclusively by RXR
homodimers have not been identified yet (24). The absence of
RXR-mediated repression in myeloid cells leads to elevated ex-
pression of prometastatic regulators, creating a tissue microenvi-
ronment favoring cancer cell extravasation and micrometastasis
formation. This process shares similarities to the formation of the
premetastatic niche, a tumor-induced receptive and supportive
tissue microenvironment that supports cancer cell colonization
and survival in a secondary organ site (25, 26). Interestingly,
several RXR-repressed genes identified in our work have been
described as important regulators involved in the formation of
premetastatic niches. We found that RXR represses both S100a4
and S100a8 in pulmonary myeloid cells. The protein products of
these genes act as central regulators during the course of pre-
metastatic niche formation by generating an inflammatory mi-
croenvironment both directly and indirectly via the up-regulation
of serum amyloid A3, resulting in enhanced cancer cell adherence
and colonization (25, 26). In addition, we found that RXRαfl/fl
pulmonary myeloid cells up-regulated TNFα, a cytokine that
has been identified as a key component of the inflammatory
milieu in the premetastatic niche in various tissue environments
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Fig. 6. RXR signaling is down-modulated in PBMCs of patients with NSCLC.
(A) Expression of RXR isotypes in PBMCs of patients with NSCLC and cancer-
free control patients. (Graphs show mean. ***adjusted P < 0.001, Mann-
Whitney test) (B) Top 10 upstream regulators by z-score predicted to be
inhibited in PBMCs of patients with NSCLC compared with cancer-free con-
trol patients (P < 0.05). RXR heterodimeric partners are shown in bold italics.
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(15, 25, 26). Similarly, versican, an extracellular matrix proteoglycan
with multifaceted roles in premetastatic niche formation, was also
up-regulated in RXRαfl/fl pulmonary myeloid cells (25, 26). In the
Lewis lung carcinoma model, tumor-derived versican activated
myeloid cells through TLR2 to induce an inflammatory micro-
environment in the premetastatic lung (15). In contrast, in the
MMTV-PyMT model of breast carcinoma, versican secreted by
CD11b+Ly6Chigh myeloid cells in premetastatic lungs stimulated
mesenchymal to epithelial transition of cancer cells, leading to
enhanced metastatic colonization (27). Another characteristic
feature of premetastatic niche is tissue remodeling and degrada-
tion of the extracellular matrix that favors extravasation of circu-
lating cancer cells (25, 26). Analogously, RXRαfl/fl myeloid cells in
the lung up-regulated several proteases capable of matrix remod-
eling, including MMP2, cathepsin B, and cathepsin S. As a con-
sequence, RXR-deficient iBMDMs had an enhanced capacity to
promote cancer cell invasion through an extracellular matrix layer.
Administration of selective RXR agonists have a well-estab-
lished beneficial effect in solid tumors because of their capacity
to induce differentiation and/or apoptosis of cancer cells (28).
Nevertheless, the influence of RXR modulation both on the
stromal compartment of primary tumor microenvironment and
on premetastatic niches remains to be determined. Our findings
suggest that the majority of genes differentially expressed in
RXRα-deficient pulmonary myeloid cells do not respond to
RXR activation. Therefore, it appears unlikely that endogenous
or synthetic RXR agonists can alter the repressive activity of the
receptor on prometastatic regulators. To therapeutically exploit
RXR’s ability to control the expression of several key regula-
tors in metastasis, RXR-specific inverse agonists could be used.
Inverse agonists have the ability to stabilize the nuclear re-
ceptor–corepressor complex and enhance transcriptional re-
pression (29). Although RXR-specific inverse agonists are not yet
available, similar compounds have already been developed and
used successfully in preclinical studies for several other nuclear
receptors including RAR, LXR, and ROR (30–33). This class of
RXR-specific ligands could enhance the repressive effect of RXR
on prometastatic regulators, potentially rendering the lung mi-
croenvironment less permissive toward metastatic colonization.
Materials and Methods
Details of mice and bone marrow transplantation, cell lines and tumor
models, histology, flow cytometry and cell sorting, RNA-seq, ChIP-seq anal-
ysis, immortalization of mouse bone marrow-derived macrophages, cancer
cell migration and invasion assays, real-time quantitative PCR, microarray
analysis, 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT)
assay, and statistical analysis are described in the SI Appendix. All experi-
ments were carried out in accordance with the institutional ethical guide-
lines at the University of Debrecen (license no.: 21/2011/DE MAAB), following
the European regulations.
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